Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 173, Issue 3, Pages 777-787
Publisher
Wiley
Online
2015-03-31
DOI
10.1111/bjd.13814
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Psoriasis Comorbidities
- (2015) Lyn Guenther et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Induction of IL-17+ T Cell Trafficking and Development by IFN- : Mechanism and Pathological Relevance in Psoriasis
- (2014) I. Kryczek et al. JOURNAL OF IMMUNOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social Life
- (2013) F Sampogna et al. ACTA DERMATO-VENEREOLOGICA
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
- (2013) Richard G. B. Langley et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psoriasis: rationale for targeting interleukin-17
- (2012) G. Girolomoni et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
- (2012) P. Rich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study
- (2012) C. Leonardi et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice
- (2012) Juul MPA van den Reek et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment
- (2012) T.C. Lucka et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
- (2012) Elizabeth A. Brezinski et al. PLoS One
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
- (2011) Yihua Cai et al. IMMUNITY
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Definition of treatment goals for moderate to severe psoriasis: a European consensus
- (2010) U. Mrowietz et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
- (2010) Wolfgang Weger BRITISH JOURNAL OF PHARMACOLOGY
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
- (2010) Andrea Chiricozzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Comorbidities in Psoriasis Patients
- (2010) Noori Kim et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Comorbidities in Patients with Psoriasis
- (2009) Alice B. Gottlieb et al. AMERICAN JOURNAL OF MEDICINE
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
- (2009) L. van der Fits et al. JOURNAL OF IMMUNOLOGY
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started